Your browser is no longer supported. Please, upgrade your browser.
RPRX Royalty Pharma plc daily Stock Chart
Royalty Pharma plc
Index- P/E14.03 EPS (ttm)3.45 Insider Own- Shs Outstand620.54M Perf Week4.07%
Market Cap30.01B Forward P/E- EPS next Y- Insider Trans- Shs Float120.85M Perf Month-
Income2.05B PEG0.50 EPS next Q- Inst Own- Short Float- Perf Quarter-
Sales1.88B P/S15.96 EPS this Y70.50% Inst Trans- Short Ratio- Perf Half Y-
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh2.73 P/C17.69 EPS next 5Y27.90% ROE- 52W Range42.00 - 56.50 Perf YTD8.67%
Dividend- P/FCF- EPS past 5Y- ROI21.30% 52W High-14.41% Beta-
Dividend %- Quick Ratio4.00 Sales past 5Y- Gross Margin- 52W Low15.14% ATR3.29
Employees35 Current Ratio4.00 Sales Q/Q15.20% Oper. Margin- RSI (14)- Volatility3.45% -
OptionableYes Debt/Eq1.15 EPS Q/Q-80.60% Profit Margin- Rel Volume0.17 Prev Close48.02
ShortableYes LT Debt/Eq1.12 Earnings- Payout- Avg Volume4.53M Price48.36
Recom2.00 SMA20-0.53% SMA50-0.53% SMA200-0.53% Volume828,365 Change0.71%
Jul-02-20 01:02PM  
Jul-01-20 01:48PM  
Jun-30-20 10:40AM  
Jun-27-20 07:13PM  
Jun-26-20 04:42PM  
Jun-25-20 07:01PM  
Jun-22-20 06:10PM  
Jun-18-20 04:15PM  
Jun-17-20 09:55AM  
Jun-16-20 06:21PM  
Jun-15-20 11:29PM  
Royalty Pharma plc operates in the biopharmaceutical industry. The company operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry. It is involved in the identification, evaluation, and acquisition of royalties and royalty-related assets on various biopharmaceutical therapies. The company collaborates with innovators from academic institutions, research hospitals, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio includes royalties on approximately 45 commercial products and three development-stage product candidates. It has royalties on various therapeutic areas and drug classes, including Neulasta, Neupogen, Rituxan, Imbruvica, Trodelvy, Tazverik, and Xtandi in oncology; Lyrica in neuropathic pain; Biktarvy, Genvoya, Prezista, Symtuza, Truvada, and Atripla in HIV; Humira, Remicade, and Cimzia TNF inhibitors; Kalydeco, Orkambi, Symdeko, and Trikafta in cystic fibrosis; Tecfidera and Tysabri in multiple sclerosis; Emgality, Nurtec ODT (rimegepant), and vazegepant in migraine; and others. The company was founded in 1996 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Coyne Terrance P.EVP & CFOJun 18Buy28.001,45040,6001,450Jun 23 09:21 PM
Coyne Terrance P.EVP & CFOJun 18Buy28.001,50042,0001,500Jun 23 09:21 PM
RIGGS RORY BDirectorJun 18Buy28.0015,000420,00015,000Jun 23 09:14 PM
Hite ChristopherEVP & Vice ChairmanJun 18Buy28.0070,0001,960,00070,000Jun 23 09:13 PM
FORD WILLIAM EDirectorJun 18Buy28.001,500,00042,000,0001,500,000Jun 22 09:55 PM
Legorreta Pablo G.CEO, Chairman of the BoardJun 18Buy28.0020,000560,00010,000Jun 22 09:55 PM
Lloyd George W.EVP, Investments & GCJun 18Buy28.0011,200313,60011,200Jun 22 09:54 PM
Lloyd George W.EVP, Investments & GCJun 18Buy28.003,00084,0003,000Jun 22 09:54 PM
Giuliani Mario GermanoDirectorJun 18Buy28.0050,0001,400,00050,000Jun 22 09:47 PM
ADAGE CAPITAL PARTNERS GP, L.L10% OwnerJun 18Buy28.003,000,00084,000,00046,015,330Jun 22 05:31 PM